Compare Citius Pharmaceuticals Inc (CTXR) vs VanEck Australian Floating Rate ETF (FLOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs VanEck Australian Floating Rate ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.75 (market cap $20.01M), while VanEck Australian Floating Rate ETF trades at $50.94. The key difference: VanEck Australian Floating Rate ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | FLOT | |
|---|---|---|
Market Cap | $20.01M | — |
Sector | Health | Sector/Thematic |
52-Week High | $1.82 | $51.09 |
52-Week Low | $0.48 | $50.72 |
Enterprise Value | $16.23M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
FLOT trades at $50.93 with minimal daily movement (+0.02%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The ETF maintains consistent dividend payments with recent distributions of $0.17-$0.18. Market focus remains on Federal Reserve policy decisions and their impact on floating rate bonds amid persistent inflation concerns.
FLOT offers exposure to high-quality floating rate bonds with a 4.0% SEC yield, positioned as a conservative income vehicle. The ETF benefits from potential Fed rate hikes but faces headwinds from inflation volatility and Treasury yield fluctuations. Current technical weakness suggests cautious near-term positioning despite the defensive characteristics of floating rate securities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →
